Fulgent Current Deferred Revenue vs Capital Surpluse Analysis
FLGT Stock | USD 22.57 0.25 1.12% |
Fulgent Genetics financial indicator trend analysis is much more than just examining Fulgent Genetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulgent Genetics is a good investment. Please check the relationship between Fulgent Genetics Current Deferred Revenue and its Capital Surpluse accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.
Current Deferred Revenue vs Capital Surpluse
Current Deferred Revenue vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulgent Genetics Current Deferred Revenue account and Capital Surpluse. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Fulgent Genetics' Current Deferred Revenue and Capital Surpluse is 0.59. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Fulgent Genetics, assuming nothing else is changed. The correlation between historical values of Fulgent Genetics' Current Deferred Revenue and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Fulgent Genetics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Current Deferred Revenue i.e., Fulgent Genetics' Current Deferred Revenue and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.59 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Capital Surpluse
Most indicators from Fulgent Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Discontinued Operations is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 93.4 M in 2024, whereas Tax Provision is likely to drop slightly above 2.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 777.1M | 366.9M | 96.6M | 179.1M | Total Revenue | 992.6M | 619.0M | 289.2M | 266.7M |
Fulgent Genetics fundamental ratios Correlations
Click cells to compare fundamentals
Fulgent Genetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fulgent Genetics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 88.8M | 700.5M | 1.3B | 1.4B | 1.3B | 1.3B | |
Other Current Liab | 3.6M | 62.7M | 36.7M | 58.4M | 49.1M | 51.6M | |
Total Current Liabilities | 6.0M | 131.1M | 112.8M | 116.2M | 73.0M | 49.4M | |
Total Stockholder Equity | 82.8M | 569.4M | 1.2B | 1.3B | 1.1B | 1.2B | |
Net Tangible Assets | 82.8M | 569.4M | 1.2B | 973.0M | 1.1B | 1.2B | |
Property Plant And Equipment Net | 6.0M | 40.2M | 62.3M | 81.4M | 94.3M | 99.0M | |
Net Debt | (9.3M) | (71.6M) | (143.6M) | (58.9M) | (82.6M) | (78.4M) | |
Retained Earnings | (63.4M) | 150.9M | 657.6M | 801M | 633.2M | 664.8M | |
Accounts Payable | 1.6M | 26.5M | 20.5M | 23.1M | 15.4M | 10.3M | |
Cash | 12.0M | 87.4M | 164.9M | 79.5M | 97.5M | 50.9M | |
Non Current Assets Total | 12.0M | 84.7M | 204.3M | 480.4M | 765.3M | 803.5M | |
Non Currrent Assets Other | (36.8M) | (88.0M) | 142.0M | (287.4M) | 32.0M | 33.6M | |
Other Assets | 251K | 44.5M | 912.6M | 26.6M | 1.0 | 0.95 | |
Cash And Short Term Investments | 70.2M | 431.9M | 935.5M | 852.9M | 424.2M | 312.5M | |
Net Receivables | 6.6M | 183.9M | 138.9M | 52.7M | 57.4M | 50.2M | |
Common Stock Shares Outstanding | 18.7M | 24.1M | 31.0M | 31.0M | 29.8M | 23.5M | |
Liabilities And Stockholders Equity | 88.8M | 700.5M | 1.3B | 1.4B | 1.3B | 1.3B | |
Inventory | 277K | 16.5M | 12.2M | 4.3M | 5.8M | 4.4M | |
Other Current Assets | 277K | (16.5M) | (12.2M) | 22.2M | 26.2M | 27.6M | |
Other Stockholder Equity | 146.1M | 418.1M | 487.1M | 477.4M | 481.3M | 258.2M | |
Total Liab | 6.0M | 131.1M | 112.8M | 116.2M | 139.8M | 146.8M | |
Property Plant And Equipment Gross | 8.6M | 41.0M | 81.9M | 124.6M | 135.1M | 141.9M | |
Total Current Assets | 76.8M | 615.7M | 1.1B | 905.6M | 507.8M | 365.6M | |
Accumulated Other Comprehensive Income | 146K | 438K | (759K) | (20.9M) | 1.2M | 1.3M | |
Property Plant Equipment | 8.6M | 40.2M | 62.3M | 98.9M | 113.8M | 119.4M | |
Retained Earnings Total Equity | (63.0M) | (63.4M) | 150.9M | 657.6M | 756.2M | 794.0M | |
Short Term Investments | 58.3M | 344.4M | 770.7M | 773.4M | 326.7M | 326.9M | |
Non Current Liabilities Total | 2.3M | 959K | 7.5M | 28.1M | 66.8M | 70.1M | |
Capital Surpluse | 114.2M | 146.1M | 418.1M | 501.9M | 577.2M | 606.1M | |
Long Term Investments | 42.8M | 132.5M | 507.0M | 339.0M | 444.0M | 466.2M | |
Non Current Liabilities Other | 2.3M | 959K | 7.5M | 28.1M | 11.0M | 6.8M | |
Net Invested Capital | 82.8M | 584.4M | 1.2B | 1.3B | 1.1B | 688.3M | |
Net Working Capital | 33.4M | 393.5M | 961.6M | 539.8M | 434.8M | 381.8M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fulgent Genetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fulgent Genetics' short interest history, or implied volatility extrapolated from Fulgent Genetics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.56) | Revenue Per Share 9.635 | Quarterly Revenue Growth (0.03) | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.